Is Evra, a transdermal, once-weekly, combined contraceptive patch cost-effective compared to combined oral contraceptives?
F.A. Sonnenberg (1), C.G. Hagerty (1), M.J. Price (2), C. Neslusan (3) UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA (1); Janssen-Cilag Ltd, High Wycombe, UK (2); Johnson & Johnson Pharmaceutical Services, Raritan, New Jersey, USA (3) Introduction: Observational studies have demonstrated that real world failure rates with COCs are considerably higher than observed in clinical trials because of inappropriate use and poor compliance. New methods that improve convenience and compliance are needed to reduce unwanted pregnancies. In clinical trials Evra, a once-weekly, transdermal, combined contraceptive patch was as effective as COCs with perfect use. Studies also showed that Evra users had better compliance than COC users. In order to predict unplanned pregnancies expected with Evra compared to COCs and to evaluate the cost-effectiveness of these two methods with typical use, a cost-effectiveness model was developed. Design & Methods: The Contraceptive Choice Mo
Related Questions
- Is Evra, a transdermal, once-weekly, combined contraceptive patch cost-effective compared to combined oral contraceptives?
- What should a woman be advised to do if she misses one combined oral contraceptive pill (OCP)?
- What should a woman do if she develops nausea on the combined oral contraceptive pill (OCP)?
